- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02810873
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
PET Imaging of Breast Cancer Using Oncogene Expression
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
I. The study's primary goal is to assess the ability of Cu-64-TP3805 (copper Cu 64 TP3805) to detect primary breast lesions as determined by the F-18-FDG (fludeoxyglucose F 18) scan.
II. The study's second goal is to determine the ability of Cu-64-TP3805 to detect primary breast lesions as determined by histology (sensitivity).
III. The study's third goal is to determine the ability of Cu-64-TP3805 to detect metastatic lesions as identified by the F-18-FDG whole-body scan.
OUTLINE: This is a dose-finding 2-stage study.
STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- Breast cancer shown with abnormal mammogram and histology verification (stage-1 patients will also need to have a positive F-18-FDG whole-body scan)
- Tumor mass of 1 cm or larger, as determined by mammography, ultrasound, or magnetic resonance imaging (MRI)
- Signed informed consent form approved by the institutional review board (IRB)
Exclusion Criteria:
- Pregnant or lactating female
- Patient with asthma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: F-18-FDG Whole body Scan
STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
|
Undergo PEM Positron Emission Mammography scan
Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
Other Names:
Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
Other Names:
|
Experimental: No F-18-FDG Scan
STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
|
Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
Other Names:
Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
Other Names:
Undergo PET Positron Emission Tomography scan
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of F-18-FDG Positive Lesions That Are Detected by the Copper Cu 64 TP3805 Analog
Time Frame: 4 hours after Cu 64 TP3805 administered
|
Cu-64 results will be compared with those of F-18-FDG for: The unit of analysis will be the lesion (with potentially multiple lesions available per patient).
|
4 hours after Cu 64 TP3805 administered
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability of Copper Cu 64 TP3805 to Detect Primary Breast Lesions as Determined by Histology (Sensitivity)
Time Frame: 4 hours after Cu 64 TP3805 administered
|
Optimal imaging time is the one (of the three) which will have least background activity in the surrounding tissue and image the maximum number of lesions with clarity.
95% confidence intervals will be used.
To account for the multiplicity of lesions per patient, the GEE approach will be used, with the robust variance.
Any adverse events will be summarized descriptively.
|
4 hours after Cu 64 TP3805 administered
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Madhukar Thakur, PhD, Thomas Jefferson University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Radiopharmaceuticals
- Trace Elements
- Micronutrients
- Copper
- Fluorodeoxyglucose F18
- Deoxyglucose
Other Study ID Numbers
- 08F.327
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Carcinoma
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in SituUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Cianna Medical, Inc.TerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Lobular Breast Carcinoma | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast CarcinomaUnited States
-
Case Comprehensive Cancer CenterWithdrawnStage I Breast Cancer | HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Canadian Cancer Trials GroupActive, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma | Ductal Breast Carcinoma | Tubular Breast Carcinoma | Medullary Breast CarcinomaUnited States, Canada
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingCancer Survivor | Invasive Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Ohio State University Comprehensive Cancer CenterWithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ
Clinical Trials on Positron Emission Mammography
-
Boston Medical CenterUnited States Department of DefenseCompletedBreast CancerUnited States
-
Swedish Medical CenterCompletedBreast Cancer | Breast Cancer SurgeryUnited States
-
University of PennsylvaniaActive, not recruiting
-
University Health Network, TorontoRecruiting
-
Memorial Sloan Kettering Cancer CenterTerminated
-
Memorial Sloan Kettering Cancer CenterGE HealthcareCompletedBreast CancerUnited States
-
University of ChicagoCompletedBreast CancerUnited States
-
M.D. Anderson Cancer CenterGE HealthcareCompletedLung CancerUnited States
-
Karolinska University HospitalRecruitingCritical Illness | Cognitive Dysfunction | TraumaSweden
-
Region GävleborgDalarna County Council, Sweden; Uppsala University Hospital; Landstinget i VärmlandUnknown